Current status of bioresorbable scaffolds in the treatment of coronary artery disease

Journal of the American College of Cardiology

Volumn 64, Issue 23, 2014, Pages 2541-2551

  Wiebe, Jens ^a   Nef, Holger M ^a   Hamm, Christian W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Bioresorbable scaffold; Coronary artery disease

Indexed keywords

ACID ANHYDRIDE; BIOMATERIAL; MAGNESIUM; POLYCARBONATE; POLYLACTIC ACID; POLYLACTIC ANHYDRIDE; TYROSINE POLYCARBONATE; UNCLASSIFIED DRUG; LACTIC ACID; POLYMER;

BIORESORBABLE SCAFFOLD; CLINICAL EVALUATION; CORONARY ARTERY DISEASE; CORONARY ARTERY OCCLUSION; CORONARY ARTERY RECANALIZATION; CORONARY BIFURCATION LESION; DRUG ELUTING STENT; ELUTION; EQUIPMENT DESIGN; HEART DISEASE; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; MEDICAL DEVICE COMPLICATION; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STENT MALAPPOSITION; STENT THROMBOSIS; ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; BIODEGRADABLE IMPLANT; DEVICES; MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS; STENT;

ABSORBABLE IMPLANTS; ACUTE CORONARY SYNDROME; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HUMANS; LACTIC ACID; MAGNESIUM; MYOCARDIAL INFARCTION; OFF-LABEL USE; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PROSTHESIS DESIGN; STENTS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84926329515     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.09.041     Document Type: Review

References (46)

1. Fihn SD, Gardin JM, Abrams J, et al., for the American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, American College of Physicians; American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons. 2012 ACCF/ACC/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44-164.
2. Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34: 2949-3003.
3. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis. Lancet 2007;370:937-48.
4. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-10.
5. Nakazawa G, Ladich E, Finn AV, et al. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention 2008;4 Suppl C: C7-10.
6. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.
7. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193-202.
8. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year followup of a randomised non-inferiority trial. Lancet 2011;378:1940-8.
9. Barlis P, Regar E, Serruys PW, et al. An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur Heart J 2010;31: 165-76.
10. Hamilos MI, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-9.
11. Lupi A, Rognoni A, Secco GG, et al. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. Eur J Prev Cardiol 2014;21:411-24.
12. Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011;58: 1325-31.
13. Kang SH, Park KW, Kang DY, et al. Biodegradable- polymer drug-eluting stents vs. stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J 2014;35:1147-58.
14. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
15. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
16. Heublein B, Rohde R, Kaese V, et al. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 2003; 89:651-6.
17. Waksman R, Pakala R, Kuchulakanti PK, et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter Cardiovasc Interv 2006;68:607-17.
18. Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836-44.
19. Abizaid A, Brachmann J, Costa JD, et al. 12-Month angiographic and clinical results of ReZolve(r) Sirolimus-Eluting Bioresorbable Coronary Scaffold: the RESTORE trial. J Am Coll Cardiol 2013;62:B13 (abstr).
20. Brugaletta S, Radu MD, Garcia-Garcia HM, et al. Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque? Atherosclerosis 2012; 221:106-12.
21. Onuma Y, Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010;122:2288-300.
22. Onuma Y, Dudek D, Thuesen L, et al. Fiveyear clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. J Am Coll Cardiol Intv 2013;6: 999-1009.
23. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
24. Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70: 515-23.
25. Tanimoto S, Bruining N, van Domburg RT, et al. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol 2008;52:1616-20.
26. Okamura T, Garg S, Gutiérrez-Chico JL, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimuseluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010;5: 932-8.
27. Ormiston JA, Serruys PW, Onuma Y, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012;5: 620-32.
28. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58:1578-88.
29. Verheye S, Ormiston JA, Stewart J, et al. A next-generation bioresorbable coronary scaffold system-from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. J Am Coll Cardiol Intv 2014;7: 89-99.
30. Brugaletta S, Heo JH, Garcia-Garcia HM, et al. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy. Eur Heart J 2012;33:1325-33.
31. Togni M, Windecker S, Cocchia R, et al. Sirolimus- eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46:231-6.
32. Nishio S, Kosuga K, Igaki K, et al. Long-term (>10 years) clinical outcomes of first-inhuman biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation 2012; 125:2343-53.
33. Farooq V, Gomez-Lara J, Brugaletta S, et al. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND single arm study. Catheter Cardiovasc Interv 2012;79: 880-8.
34. Whitbourn RJ. ABSORB EXTEND: an interim report of the 24-month clinical outcomes from the first 250 patients enrolled. J Am Coll Cardiol 2013; 62:B11 (abstr).
35. Leon M. The DESolve Nx Novolimus-Eluting Bioresorbable Coronary Scaffold: first report of one-year clinical and CT imaging results. Paper presented at: Transcatheter Cardiovascular Therapeutics; October 29, 2013; San Francisco, CA.
36. Gori T, Schulz E, Hink U, et al. Early outcome after implantation of Absorb bioresorbable drugeluting scaffolds in patients with acute coronary syndromes. EuroIntervention 2014;9:1036-41.
37. Wiebe J, Möllmann H, Most A, et al. Shortterm outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol 2014;103:141-8.
38. Muramatsu T, Onuma Y, van Geuns RJ, et al., for the ABSORB Cohort B Investigators, ABSORB EXTEND Investigators, SPIRIT FIRST Investigators, SPIRIT II Investigators, SPIRIT III Investigators, SPIRIT IV Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. J Am Coll Cardiol Intv 2014;7: 482-93.
39. Fernández D, Brugaletta S, Martín-Yuste V, et al. First experience of a bioresorbable vascular scaffold implantation in left main stenosis. Int J Cardiol 2013;168:1566-8.
40. Diletti R, Farooq V, Girasis C, et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013;99: 98-105.
41. Dörr O, Liebetrau C, Wiebe J, et al. Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart Vessels 2014 Jan 4 [E-pub ahead of print].
42. Dörr O, Liebetrau C, Hecker F, et al. Full bioresorbable jacket. Herz 2013 Aug 2 [E-pub ahead of print].
43. Grundeken MJ, Kraak RP, de Bruin DM, et al. Three-dimensional optical coherence tomography evaluation of a left main bifurcation lesion treated with ABSORB® bioresorbable vascular scaffold including fenestration and dilatation of the side branch. Int J Cardiol 2013;168:e107-8.
44. Ormiston JA, Webber B, Ubod B, Webster MW, White J. Absorb everolimus-eluting bioresorbable scaffolds in coronary bifurcations: a bench study of deployment, side branch dilatation and postdilatation strategies. EuroIntervention 2014 May 20 [E-pub ahead of print].
45. Gori T, Guagliumi G, Münzel T. Absorb bioresorbable scaffold implantation for the treatment of an ostial chronic total occlusion. Int J Cardiol 2014;172:e377-8.
46. Ong PJ, Jafary FH, Ho HH. "First-in-man" use of bioresorbable vascular scaffold in saphenous vein graft. EuroIntervention 2013;9:165.